Paysign (NASDAQ:PAYS) Issues Earnings Results

Paysign (NASDAQ:PAYS) announced its quarterly earnings data on Monday. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02, FiscalAI reports. The business had revenue of $30.80 million during the quarter, compared to analyst estimates of $29.02 million. Paysign had a return on equity of 37.20% and a net margin of 18.48%.

Here are the key takeaways from Paysign’s conference call:

• Paysign reported record third-quarter revenue of $30.8 million, up 43%, with net income rising more than 200% to $6.7 million. Patient affordability revenue more than doubled, and gross margin expanded 840 basis points to 64.7% as the higher-margin business grew.
• The company expects 2026 revenue of $114 million–$117 million and raised its outlook for profitability, forecasting gross margin of 63.5%–64.5%, net income of $23 million–$24 million, and Adjusted EBITDA of $38.5 million–$40 million. It expects to end the year with 190–195 active affordability programs.
• A plasma customer is moving 113 centers to another provider by year-end, reducing fourth-quarter revenue by an estimated $1.5 million and gross profit by $700,000. Paysign expects to end 2026 with 445–450 centers, down from 562 at quarter-end, though management expects new centers to offset the loss over the next few quarters.
• Apherion’s donor management system remains under regulatory review, with no approval timeline provided. Management said interest is strong in the U.S. and Europe and expects a faster commercial ramp once the product is cleared.

Paysign Trading Down 2.7%

Shares of PAYS stock traded down $0.27 on Wednesday, hitting $9.87. 831,575 shares of the stock were exchanged, compared to its average volume of 754,648. The firm has a market capitalization of $557.28 million, a P/E ratio of 29.85 and a beta of 0.92. The business has a 50-day moving average of $13.82 and a 200 day moving average of $8.63. Paysign has a fifty-two week low of $3.08 and a fifty-two week high of $16.15.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PAYS. Lake Street Capital boosted their target price on Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Barrington Research set a $15.00 price objective on shares of Paysign in a report on Tuesday, August 11th. Maxim Group lowered shares of Paysign from a “buy” rating to a “hold” rating in a report on Wednesday. Wall Street Zen downgraded shares of Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Finally, DA Davidson upped their target price on shares of Paysign from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, September 30th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Paysign has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Paysign News Summary

Investors following PAYS have been watching these news items:

• Positive Sentiment: Q3 revenue reached a record $30.8 million, up 42.6% year over year, while EPS of $0.11 beat the $0.09 consensus. Operating margin more than tripled to 23.8%, and pharma revenue rose 109.8%. Paysign Q3 2026 results
• Negative Sentiment: Paysign’s FY 2026 EPS guidance of $0.37–$0.38 is below the $0.51 consensus, despite revenue guidance of $114 million–$117 million being broadly in line with the $114.7 million estimate. 2026 revenue and margin outlook
• Negative Sentiment: A customer’s pullback is raising concerns about future revenue, and Maxim Group downgraded the stock from “buy” to “hold,” adding potential pressure after the earnings update. Customer pullback weighs on future revenue Maxim Group ratings

Insider Transactions at Paysign

In related news, insider Michael Ngo sold 79,925 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $12.74, for a total transaction of $1,018,244.50. Following the completion of the transaction, the insider owned 2,350,000 shares in the company, valued at approximately $29,939,000. This represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joan Herman sold 38,900 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $11.74, for a total transaction of $456,686.00. Following the transaction, the executive vice president owned 609,421 shares of the company’s stock, valued at approximately $7,154,602.54. This represents a 6.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 259,904 shares of company stock valued at $3,402,424 over the last 90 days. 24.50% of the stock is owned by corporate insiders.

About Paysign

Paysign, Inc. provides prepaid card programs, payment processing and related financial technology services. Its platform supports organizations that need to distribute funds and manage payments, including businesses in the healthcare sector. The company serves plasma collection centers with donor compensation and payment solutions, and works with pharmaceutical companies on patient assistance and affordability programs. Its services also support payments for clinical trials and other disbursement needs.